Helsinn is transforming into a leading oncology company, with a comprehensive portfolio of cancer and rare disease products and therapies helping to improve the lives of patients all around the world. We work with a host of longstanding worldwide partners who share our vision and values, with a unique business model combining integrated early- and late-stage licensing programs to complement our own drug discovery and development.
Helsinn's Business Strategy
Since its foundation, the Helsinn Group has had a unique integrated business model, focused on the in- and out-licensing of pharmaceuticals. We have recently started to build on our leading position in cancer care, expanding into cancer therapeutics.
Helsinn out-licenses its products to commercial partners in its global distribution network while promoting and distributing to the cancer-care community in the US through our subsidiary Helsinn Therapeutics.
We start the process with the identification of innovative NCEs in the development phase, which are then in-licensed by acquiring the worldwide rights.
Once we have a product aligned with our mission and portfolio, we utilize our integrated capabilities and our in-house knowledge to complete development, and secure marketing approvals and commercialization worldwide either directly or through our partners.